CDNA:CA:TSX-CI Bio-Revolution Index ETF (CAD)

ETF | Others |

Last Closing

CAD 17.12

Change

+0.25 (+1.48)%

Market Cap

CAD 6.10M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.06 (-0.22%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 5.46B
XEQT:CA iShares Core Equity Portfolio

-0.01 (-0.03%)

CAD 5.15B
PHYS-U:CA Sprott Physical Gold Trust

+0.16 (+0.75%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.07 (+0.19%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

-0.28 (-0.61%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.40 (+1.54%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.26 (+2.28%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.01 (-0.04%)

CAD 2.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

CAD 2.59B

ETFs Containing CDNA:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.17% 6% D- 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.17% 6% D- 21% F
Trailing 12 Months  
Capital Gain 12.04% 33% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.04% 33% F 37% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.39% 5% F 11% F
Dividend Return -4.39% 4% F 9% A-
Total Return 0.00% 4% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 7.48% 57% F 80% B-
Risk Adjusted Return -58.66% 4% F 4% F
Market Capitalization 6.10M 18% F 6% D-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.